Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. (Q42983598)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

title

Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Bertrand Nalpas

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

author name string

P Lebray

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

H Zylberberg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

B Poulet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

F Carnot

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

S Martin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Y Chretien

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

S Pol

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

S Caillat-Zuckman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

C Bréchot

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

publication date

1 March 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

24 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

page(s)

175-182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

24 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

A new syndrome of liver iron overload with normal transferrin saturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Pathophysiology of iron toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Hemochromatosis in heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

Major histocompatibility complex class I associations in iron overload: evidence for a new link between the HFE H63D mutation, HLA-A29, and non-classical forms of hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00488.X

10.1046/J.1365-2893.2003.00488.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14996353%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

1 reference